Initiation of Phase I Study of ACI-3024 Small Molecule Tau Morphomer by AC Immune SA

A Swiss-based clinical-stage biopharma firm, AC Immune SA, made an announcement today about the dosing of the first subject in a Phase I study of ACI-3024, which is a first-in-class trial oral small molecule Tau Morphomer inhibitor which will be studied in neurodegenerative diseases which are characterized by the presence of pathological Tau aggregates. This will be the first significant advancement in AC Immune’s collaboration with Eli Lilly and Company.

The Chief Executive Officer of AC Immune SA, Professor Andrea Pfeifer commented that the initiation of this study is a significant milestone for AC Immune in our collaboration with Lilly for patients who are suffering from debilitating neurodegenerative diseases. It gives a demonstration of the productivity of our exclusive small molecule Morphomer discovery platform & further advance our robust clinical pipeline in order to address neurodegenerative diseases, in particular for diagnostics and therapeutics targeting Tau. Addressing Tau pathology with precision medicine is a crucial therapeutic strategy for Alzheimer’s disease, as well as, other neurodegenerative diseases.

ACI-3024 is the main focus of a license & collaboration contract between AC Immune & Lilly to research and then develop small molecule Tau aggregation inhibitors for the treatment of Alzheimer’s disease & other neurodegenerative diseases. AC Immune’s exclusive Morphomer discovery platform & initial development experience will be integrated with Lilly’s recognized clinical development expertise & viable capabilities in central nervous system disorders through the collaboration. Lilly will be funding and conducting further clinical development whereas AC Immune will be conducting the initial Phase I development of the Morphomer Tau aggregation inhibitors.

The Phase I trial is a randomized, control, double-blind, progressive single & multiple ascending dose study with open-label food effect & pharmacodynamics assessment arms to evaluate the tolerability, safety, pharmacodynamics, and pharmacokinetics of ACI-3024 in healthy volunteers.